AIP
ORMP icon

Ameritas Investment Partners’s Oramed Pharmaceuticals ORMP Stock Holding History

Ameritas Investment Partners’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,094
Closed -$18K – 3188
2022
Q1 		$18K Hold
2,094
– – ﹤0.01% 2603
2021
Q4 		$30K Hold
2,094
– – ﹤0.01% 2437
2021
Q3 		$46K Hold
2,094
– – ﹤0.01% 2221
2021
Q2 		$28K Buy
+2,094
New +$23.9K ﹤0.01% 2553

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameritas Investment Partners's ORMP Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 2,094 shares — an estimated $18K sold.

Ameritas Investment Partners first reported a position in ORMP in Q2 2021 and held it in 4 quarters. The position peaked at $46K in Q3 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,094 Oramed Pharmaceuticals shares in Q2 2022, an estimated $18K.
  • Ameritas Investment Partners first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Ameritas Investment Partners's Oramed Pharmaceuticals position peaked at $46K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.